Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now small index

Tricuspid Valve Disease clinical trials

6 of 7 indexed Tricuspid Valve Disease trials are currently recruiting.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 6 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Tricuspid Valve Disease: 7 US clinical trials tracked, 6 recruiting.

Tricuspid Valve Disease is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. The most active sponsor is Corvivo Cardiovascular, running 2 of these trials.

Enrollment posture brief

Registry condition tricuspid-valve-disease

OPEN 6 | RECR 86% | LATE 0 | EARLY 0 | RANK #2497 | SPON 2

Nearest open-share peer: Adenovirus (86% recruiting · 7 trials)

Tricuspid Valve Disease (thi…86%ACL Tear71.4%ACL57.1%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Tricuspid Valve Disease

Tricuspid Valve Disease lists 6 open slots (86% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Tricuspid Valve Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Tricuspid Valve Disease is recruiting above its size-band peers.

    6 of 7 indexed trials (85.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Tricuspid Valve Disease research.

    Corvivo Cardiovascular accounts for 2 of 7 trials (28.6%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Tricuspid Valve Disease trials plan to enrol fewer than 100 people.

    Median target enrolment is 78 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.

  4. Tricuspid Valve Disease research is mostly interventional.

    7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase Distribution

Phase data not available

Top Sponsors

Named interventions

Most-linked intervention names on Tricuspid Valve Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Optimal Medical Therapy Drug
2 trials
Edwards EVOQUE System Device
1 trials
TricValve® Transcatheter Bicaval Valve System Device
1 trials
DUO Transcatheter Tricuspid Coaptation Valve System Device
1 trials
Tricuspid valve replacement with the Cor TRICUSPID ECM Valve Device
1 trials
CorMatrix Cor TRICUSPID ECM Valve Device
1 trials
Edwards PASCAL System Device
1 trials
VDyne Transcatheter Tricuspid Valve Replacement System Device
1 trials

US sites by state

Facility locations filed on Tricuspid Valve Disease trials. A trial with sites in several states counts in each.

Indiana 5 trials
California 5 trials
New York 4 trials
Illinois 4 trials
Arizona 4 trials
Ohio 3 trials
Minnesota 3 trials
Georgia 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Tricuspid Valve Disease page

7 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Tricuspid Valve Disease condition card totals 7 registered trials; most-linked intervention Optimal Medical Therapy; top US site state Indiana. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.